Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 16 studies | 25% ± 12% | |
peripheral blood | 8 studies | 20% ± 4% | |
intestine | 5 studies | 25% ± 12% | |
kidney | 5 studies | 18% ± 2% | |
brain | 5 studies | 23% ± 6% | |
uterus | 4 studies | 24% ± 5% | |
pancreas | 3 studies | 24% ± 5% | |
placenta | 3 studies | 26% ± 8% | |
breast | 3 studies | 19% ± 1% | |
liver | 3 studies | 24% ± 8% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 2873.75 | 1444 / 1445 | 100% | 84.63 | 183 / 183 |
lung | 100% | 4645.85 | 577 / 578 | 100% | 66.20 | 1152 / 1155 |
ovary | 100% | 3435.41 | 180 / 180 | 99% | 84.62 | 426 / 430 |
intestine | 100% | 3317.27 | 966 / 966 | 99% | 70.45 | 522 / 527 |
uterus | 100% | 2957.61 | 170 / 170 | 98% | 87.14 | 448 / 459 |
bladder | 100% | 2484.05 | 21 / 21 | 97% | 61.02 | 488 / 504 |
kidney | 100% | 3693.78 | 89 / 89 | 97% | 57.56 | 871 / 901 |
breast | 100% | 4497.47 | 459 / 459 | 96% | 44.62 | 1076 / 1118 |
pancreas | 97% | 2043.97 | 317 / 328 | 98% | 71.12 | 174 / 178 |
stomach | 94% | 1938.12 | 337 / 359 | 99% | 71.06 | 284 / 286 |
thymus | 100% | 2731.03 | 651 / 653 | 92% | 26.64 | 558 / 605 |
skin | 91% | 1986.78 | 1641 / 1809 | 93% | 46.63 | 439 / 472 |
prostate | 99% | 2529.58 | 243 / 245 | 78% | 20.62 | 391 / 502 |
adrenal gland | 99% | 1823.72 | 256 / 258 | 63% | 12.85 | 145 / 230 |
liver | 94% | 1895.00 | 213 / 226 | 64% | 21.43 | 259 / 406 |
brain | 61% | 798.13 | 1604 / 2642 | 62% | 25.64 | 436 / 705 |
adipose | 100% | 5275.06 | 1204 / 1204 | 0% | 0 | 0 / 0 |
spleen | 100% | 3743.87 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 90.15 | 45 / 45 |
blood vessel | 99% | 2819.77 | 1327 / 1335 | 0% | 0 | 0 / 0 |
peripheral blood | 99% | 4927.13 | 917 / 929 | 0% | 0 | 0 / 0 |
heart | 92% | 1440.50 | 796 / 861 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 86% | 34.09 | 25 / 29 |
muscle | 40% | 414.96 | 324 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 26% | 4.63 | 21 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_2000373 | Biological process | positive regulation of DNA topoisomerase (ATP-hydrolyzing) activity |
GO_0045071 | Biological process | negative regulation of viral genome replication |
GO_0070782 | Biological process | phosphatidylserine exposure on apoptotic cell surface |
GO_0006953 | Biological process | acute-phase response |
GO_0060368 | Biological process | regulation of Fc receptor mediated stimulatory signaling pathway |
GO_0010628 | Biological process | positive regulation of gene expression |
GO_0051607 | Biological process | defense response to virus |
GO_0010288 | Biological process | response to lead ion |
GO_0006659 | Biological process | phosphatidylserine biosynthetic process |
GO_0033003 | Biological process | regulation of mast cell activation |
GO_0045089 | Biological process | positive regulation of innate immune response |
GO_0030168 | Biological process | platelet activation |
GO_0046718 | Biological process | symbiont entry into host cell |
GO_0050765 | Biological process | negative regulation of phagocytosis |
GO_1905820 | Biological process | positive regulation of chromosome separation |
GO_0006915 | Biological process | apoptotic process |
GO_0017121 | Biological process | plasma membrane phospholipid scrambling |
GO_0035456 | Biological process | response to interferon-beta |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0005730 | Cellular component | nucleolus |
GO_0005886 | Cellular component | plasma membrane |
GO_0045121 | Cellular component | membrane raft |
GO_0048471 | Cellular component | perinuclear region of cytoplasm |
GO_0016020 | Cellular component | membrane |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005794 | Cellular component | Golgi apparatus |
GO_0062023 | Cellular component | collagen-containing extracellular matrix |
GO_0005829 | Cellular component | cytosol |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0003677 | Molecular function | DNA binding |
GO_0019899 | Molecular function | enzyme binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0045340 | Molecular function | mercury ion binding |
GO_0017128 | Molecular function | phospholipid scramblase activity |
GO_0005154 | Molecular function | epidermal growth factor receptor binding |
GO_0001618 | Molecular function | virus receptor activity |
GO_0000287 | Molecular function | magnesium ion binding |
GO_0032791 | Molecular function | lead ion binding |
GO_0008270 | Molecular function | zinc ion binding |
GO_0004518 | Molecular function | nuclease activity |
GO_0042609 | Molecular function | CD4 receptor binding |
GO_0005509 | Molecular function | calcium ion binding |
GO_0005515 | Molecular function | protein binding |
GO_0017124 | Molecular function | SH3 domain binding |
Gene name | PLSCR1 |
Protein name | Phospholipid scramblase Phospholipid scramblase 1 Phospholipid scramblase 1 (PL scramblase 1) (Ca(2+)-dependent phospholipid scramblase 1) (Erythrocyte phospholipid scramblase) (Mg(2+)-dependent nuclease) (EC 3.1.-.-) (MmTRA1b) PLSCR1 protein (Phospholipid scramblase 1, isoform CRA_f) |
Synonyms | hCG_17108 |
Description | FUNCTION: Catalyzes calcium-induced ATP-independent rapid bidirectional and non-specific movement of phospholipids (lipid scrambling or lipid flip-flop) between the inner and outer leaflet of the plasma membrane resulting in collapse of the phospholipid asymmetry which leads to phosphatidylserine externalization on the cell surface . Mediates calcium-dependent phosphatidylserine externalization and apoptosis in neurons via its association with TRPC5 (By similarity). Also exhibits magnesium-dependent nuclease activity against double-stranded DNA and RNA but not single-stranded DNA and can enhance DNA decatenation mediated by TOP2A . Negatively regulates FcR-mediated phagocytosis in differentiated macrophages . May contribute to cytokine-regulated cell proliferation and differentiation (By similarity). May play a role in the antiviral response of interferon (IFN) by amplifying and enhancing the IFN response through increased expression of select subset of potent antiviral genes . Inhibits the functions of viral transactivators, including human T-cell leukemia virus (HTLV)-1 protein Tax, human immunodeficiency virus (HIV)-1 Tat, human hepatitis B virus (HBV) HBx, Epstein-Barr virus (EBV) BZLF1 and human cytomegalovirus IE1 and IE2 proteins through direct interactions . Mediates also the inhibition of influenza virus infection by preventing nuclear import of the viral nucleoprotein/NP . Plays a crucial role as a defense factor against SARS-CoV-2 independently of its scramblase activity by directly targeting nascent viral vesicles to prevent virus-membrane fusion and the release of viral RNA into the host-cell cytosol . .; FUNCTION: (Microbial infection) Acts as an attachment receptor for HCV. . FUNCTION: May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. . FUNCTION: May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. . FUNCTION: May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. . FUNCTION: May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. . FUNCTION: May mediate accelerated ATP-independent bidirectional transbilayer migration of phospholipids upon binding calcium ions that results in a loss of phospholipid asymmetry in the plasma membrane. . |
Accessions | ENST00000468985.5 ENST00000493432.5 ENST00000489775.5 C9J0H3 ENST00000478267.5 F2Z3F2 ENST00000483300.5 H7C5I5 ENST00000463777.5 ENST00000462666.5 C9J9P4 C9J7K9 ENST00000448787.6 [O15162-2] ENST00000487389.5 C9JE06 ENST00000486631.5 Q8WVK1 O15162 ENST00000488253.5 ENST00000472349.1 ENST00000342435.9 [O15162-1] |